The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Non-prescription Drugs-Global Market Insights and Sales Trends 2024
Synopsis
A medication (also referred to as medicine, pharmaceutical drug, or simply drug) is a drug used to diagnose, cure, treat, or prevent disease. Drug therapy (pharmacotherapy) is an important part of the medical field and relies on the science of pharmacology for continual advancement and on pharmacy for appropriate management.
The global Non-prescription Drugs market size is expected to reach US$ 182520 million by 2029, growing at a CAGR of 5.5% from 2023 to 2029. The market is mainly driven by the significant applications of Non-prescription Drugs in various end use industries. The expanding demands from the Hospital, Clinic and Other, are propelling Non-prescription Drugs market. Brand Drugs, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Generic Drug segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Non-prescription Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Non-prescription Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Non-prescription Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Non-prescription Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Non-prescription Drugs covered in this report include Pfizer, Roche, Sanofi, Johnson & Johnson, Merck & Co. (MSD), Novartis, AbbVie, Gilead Sciences and GlaxoSmithKline (GSK), etc.
The global Non-prescription Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
Roche
Sanofi
Johnson & Johnson
Merck & Co. (MSD)
Novartis
AbbVie
Gilead Sciences
GlaxoSmithKline (GSK)
Amgen
AstraZeneca
Bristol-Myers Squibb
Eli Lilly
Teva
Bayer
Novo Nordisk
AbbVie
Takeda
Boehringer Ingelheim
Takeda
Global Non-prescription Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Non-prescription Drugs market, Segment by Type:
Brand Drugs
Generic Drug
Global Non-prescription Drugs market, by Application
Hospital
Clinic
Other
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Non-prescription Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
A medication (also referred to as medicine, pharmaceutical drug, or simply drug) is a drug used to diagnose, cure, treat, or prevent disease. Drug therapy (pharmacotherapy) is an important part of the medical field and relies on the science of pharmacology for continual advancement and on pharmacy for appropriate management.
The global Non-prescription Drugs market size is expected to reach US$ 182520 million by 2029, growing at a CAGR of 5.5% from 2023 to 2029. The market is mainly driven by the significant applications of Non-prescription Drugs in various end use industries. The expanding demands from the Hospital, Clinic and Other, are propelling Non-prescription Drugs market. Brand Drugs, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Generic Drug segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Non-prescription Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Non-prescription Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Non-prescription Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Non-prescription Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Non-prescription Drugs covered in this report include Pfizer, Roche, Sanofi, Johnson & Johnson, Merck & Co. (MSD), Novartis, AbbVie, Gilead Sciences and GlaxoSmithKline (GSK), etc.
The global Non-prescription Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
Roche
Sanofi
Johnson & Johnson
Merck & Co. (MSD)
Novartis
AbbVie
Gilead Sciences
GlaxoSmithKline (GSK)
Amgen
AstraZeneca
Bristol-Myers Squibb
Eli Lilly
Teva
Bayer
Novo Nordisk
AbbVie
Takeda
Boehringer Ingelheim
Takeda
Global Non-prescription Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Non-prescription Drugs market, Segment by Type:
Brand Drugs
Generic Drug
Global Non-prescription Drugs market, by Application
Hospital
Clinic
Other
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Non-prescription Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Non-prescription Drugs
1.1 Non-prescription Drugs Market Overview
1.1.1 Non-prescription Drugs Product Scope
1.1.2 Non-prescription Drugs Market Status and Outlook
1.2 Global Non-prescription Drugs Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Non-prescription Drugs Market Size by Region (2018-2029)
1.4 Global Non-prescription Drugs Historic Market Size by Region (2018-2023)
1.5 Global Non-prescription Drugs Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Non-prescription Drugs Market Size (2018-2029)
1.6.1 North America Non-prescription Drugs Market Size (2018-2029)
1.6.2 Europe Non-prescription Drugs Market Size (2018-2029)
1.6.3 Asia-Pacific Non-prescription Drugs Market Size (2018-2029)
1.6.4 Latin America Non-prescription Drugs Market Size (2018-2029)
1.6.5 Middle East & Africa Non-prescription Drugs Market Size (2018-2029)
2 Non-prescription Drugs Market by Type
2.1 Introduction
2.1.1 Brand Drugs
2.1.2 Generic Drug
2.2 Global Non-prescription Drugs Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Non-prescription Drugs Historic Market Size by Type (2018-2023)
2.2.2 Global Non-prescription Drugs Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Non-prescription Drugs Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Non-prescription Drugs Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Non-prescription Drugs Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Non-prescription Drugs Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Non-prescription Drugs Revenue Breakdown by Type (2018-2029)
3 Non-prescription Drugs Market Overview by Application
3.1 Introduction
3.1.1 Hospital
3.1.2 Clinic
3.1.3 Other
3.2 Global Non-prescription Drugs Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Non-prescription Drugs Historic Market Size by Application (2018-2023)
3.2.2 Global Non-prescription Drugs Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Non-prescription Drugs Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Non-prescription Drugs Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Non-prescription Drugs Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Non-prescription Drugs Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Non-prescription Drugs Revenue Breakdown by Application (2018-2029)
4 Non-prescription Drugs Competition Analysis by Players
4.1 Global Non-prescription Drugs Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Non-prescription Drugs as of 2022)
4.3 Date of Key Players Enter into Non-prescription Drugs Market
4.4 Global Top Players Non-prescription Drugs Headquarters and Area Served
4.5 Key Players Non-prescription Drugs Product Solution and Service
4.6 Competitive Status
4.6.1 Non-prescription Drugs Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Pfizer
5.1.1 Pfizer Profile
5.1.2 Pfizer Main Business
5.1.3 Pfizer Non-prescription Drugs Products, Services and Solutions
5.1.4 Pfizer Non-prescription Drugs Revenue (US$ Million) & (2018-2023)
5.1.5 Pfizer Recent Developments
5.2 Roche
5.2.1 Roche Profile
5.2.2 Roche Main Business
5.2.3 Roche Non-prescription Drugs Products, Services and Solutions
5.2.4 Roche Non-prescription Drugs Revenue (US$ Million) & (2018-2023)
5.2.5 Roche Recent Developments
5.3 Sanofi
5.3.1 Sanofi Profile
5.3.2 Sanofi Main Business
5.3.3 Sanofi Non-prescription Drugs Products, Services and Solutions
5.3.4 Sanofi Non-prescription Drugs Revenue (US$ Million) & (2018-2023)
5.3.5 Johnson & Johnson Recent Developments
5.4 Johnson & Johnson
5.4.1 Johnson & Johnson Profile
5.4.2 Johnson & Johnson Main Business
5.4.3 Johnson & Johnson Non-prescription Drugs Products, Services and Solutions
5.4.4 Johnson & Johnson Non-prescription Drugs Revenue (US$ Million) & (2018-2023)
5.4.5 Johnson & Johnson Recent Developments
5.5 Merck & Co. (MSD)
5.5.1 Merck & Co. (MSD) Profile
5.5.2 Merck & Co. (MSD) Main Business
5.5.3 Merck & Co. (MSD) Non-prescription Drugs Products, Services and Solutions
5.5.4 Merck & Co. (MSD) Non-prescription Drugs Revenue (US$ Million) & (2018-2023)
5.5.5 Merck & Co. (MSD) Recent Developments
5.6 Novartis
5.6.1 Novartis Profile
5.6.2 Novartis Main Business
5.6.3 Novartis Non-prescription Drugs Products, Services and Solutions
5.6.4 Novartis Non-prescription Drugs Revenue (US$ Million) & (2018-2023)
5.6.5 Novartis Recent Developments
5.7 AbbVie
5.7.1 AbbVie Profile
5.7.2 AbbVie Main Business
5.7.3 AbbVie Non-prescription Drugs Products, Services and Solutions
5.7.4 AbbVie Non-prescription Drugs Revenue (US$ Million) & (2018-2023)
5.7.5 AbbVie Recent Developments
5.8 Gilead Sciences
5.8.1 Gilead Sciences Profile
5.8.2 Gilead Sciences Main Business
5.8.3 Gilead Sciences Non-prescription Drugs Products, Services and Solutions
5.8.4 Gilead Sciences Non-prescription Drugs Revenue (US$ Million) & (2018-2023)
5.8.5 Gilead Sciences Recent Developments
5.9 GlaxoSmithKline (GSK)
5.9.1 GlaxoSmithKline (GSK) Profile
5.9.2 GlaxoSmithKline (GSK) Main Business
5.9.3 GlaxoSmithKline (GSK) Non-prescription Drugs Products, Services and Solutions
5.9.4 GlaxoSmithKline (GSK) Non-prescription Drugs Revenue (US$ Million) & (2018-2023)
5.9.5 GlaxoSmithKline (GSK) Recent Developments
5.10 Amgen
5.10.1 Amgen Profile
5.10.2 Amgen Main Business
5.10.3 Amgen Non-prescription Drugs Products, Services and Solutions
5.10.4 Amgen Non-prescription Drugs Revenue (US$ Million) & (2018-2023)
5.10.5 Amgen Recent Developments
5.11 AstraZeneca
5.11.1 AstraZeneca Profile
5.11.2 AstraZeneca Main Business
5.11.3 AstraZeneca Non-prescription Drugs Products, Services and Solutions
5.11.4 AstraZeneca Non-prescription Drugs Revenue (US$ Million) & (2018-2023)
5.11.5 AstraZeneca Recent Developments
5.12 Bristol-Myers Squibb
5.12.1 Bristol-Myers Squibb Profile
5.12.2 Bristol-Myers Squibb Main Business
5.12.3 Bristol-Myers Squibb Non-prescription Drugs Products, Services and Solutions
5.12.4 Bristol-Myers Squibb Non-prescription Drugs Revenue (US$ Million) & (2018-2023)
5.12.5 Bristol-Myers Squibb Recent Developments
5.13 Eli Lilly
5.13.1 Eli Lilly Profile
5.13.2 Eli Lilly Main Business
5.13.3 Eli Lilly Non-prescription Drugs Products, Services and Solutions
5.13.4 Eli Lilly Non-prescription Drugs Revenue (US$ Million) & (2018-2023)
5.13.5 Eli Lilly Recent Developments
5.14 Teva
5.14.1 Teva Profile
5.14.2 Teva Main Business
5.14.3 Teva Non-prescription Drugs Products, Services and Solutions
5.14.4 Teva Non-prescription Drugs Revenue (US$ Million) & (2018-2023)
5.14.5 Teva Recent Developments
5.15 Bayer
5.15.1 Bayer Profile
5.15.2 Bayer Main Business
5.15.3 Bayer Non-prescription Drugs Products, Services and Solutions
5.15.4 Bayer Non-prescription Drugs Revenue (US$ Million) & (2018-2023)
5.15.5 Bayer Recent Developments
5.16 Novo Nordisk
5.16.1 Novo Nordisk Profile
5.16.2 Novo Nordisk Main Business
5.16.3 Novo Nordisk Non-prescription Drugs Products, Services and Solutions
5.16.4 Novo Nordisk Non-prescription Drugs Revenue (US$ Million) & (2018-2023)
5.16.5 Novo Nordisk Recent Developments
5.17 AbbVie
5.17.1 AbbVie Profile
5.17.2 AbbVie Main Business
5.17.3 AbbVie Non-prescription Drugs Products, Services and Solutions
5.17.4 AbbVie Non-prescription Drugs Revenue (US$ Million) & (2018-2023)
5.17.5 AbbVie Recent Developments
5.18 Takeda
5.18.1 Takeda Profile
5.18.2 Takeda Main Business
5.18.3 Takeda Non-prescription Drugs Products, Services and Solutions
5.18.4 Takeda Non-prescription Drugs Revenue (US$ Million) & (2018-2023)
5.18.5 Takeda Recent Developments
5.19 Boehringer Ingelheim
5.19.1 Boehringer Ingelheim Profile
5.19.2 Boehringer Ingelheim Main Business
5.19.3 Boehringer Ingelheim Non-prescription Drugs Products, Services and Solutions
5.19.4 Boehringer Ingelheim Non-prescription Drugs Revenue (US$ Million) & (2018-2023)
5.19.5 Boehringer Ingelheim Recent Developments
5.20 Takeda
5.20.1 Takeda Profile
5.20.2 Takeda Main Business
5.20.3 Takeda Non-prescription Drugs Products, Services and Solutions
5.20.4 Takeda Non-prescription Drugs Revenue (US$ Million) & (2018-2023)
5.20.5 Takeda Recent Developments
6 North America
6.1 North America Non-prescription Drugs Market Size by Country (2018-2029)
6.2 the United States
6.3 Canada
7 Europe
7.1 Europe Non-prescription Drugs Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Non-prescription Drugs Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Non-prescription Drugs Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Non-prescription Drugs Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Non-prescription Drugs Market Dynamics
11.1 Non-prescription Drugs Industry Trends
11.2 Non-prescription Drugs Market Drivers
11.3 Non-prescription Drugs Market Challenges
11.4 Non-prescription Drugs Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
